Open main menu
Home
Random
Recent changes
Special pages
Community portal
Preferences
About Wikipedia
Disclaimers
Incubator escapee wiki
Search
User menu
Talk
Dark mode
Contributions
Create account
Log in
Editing
Malignancy
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
==Epidemiology== Malignancy has been a constant global health concern for a number of years, resulting in significant social and economic impacts on individuals with malignancy and their families.<ref>{{cite journal | journal = Australian Institute of Health and Welfare | title = Cancer data in Australia, cancer incidence and survival by stage data visualisation | url = https://www.aihw.gov.au/reports/cancer/cancer-data-in-australia/contents/cancer-incidence-and-survival-by-stage-data-visualisation }}</ref> The risk of developing malignancy is 20.2%.<ref name = "Mattiuzzi_2019">{{cite journal | vauthors = Mattiuzzi C, Lippi G | title = Current Cancer Epidemiology | journal = Journal of Epidemiology and Global Health | volume = 9 | issue = 4 | pages = 217β222 | date = December 2019 | pmid = 31854162 | pmc = 7310786 | doi = 10.2991/jegh.k.191008.001 }}</ref> In 2018, 18 million patients were diagnosed with a malignant tumour with lung, breast and prostate being the most common form.<ref name = "Mattiuzzi_2019" /> Additionally, there were approximately 10 million mortalities due to cancer in 2020<ref name = "WHO_Cancer" /> and, there is an overall trend which demonstrated that malignant mortality has increased by 28% over the past 15 years.<ref name = "Mattiuzzi_2019" /> Lung cancer has the highest mortality rate in comparison to other forms of cancer, with the leading cause of development due to smoking.<ref name="Bender_2014">{{cite journal | vauthors = Bender E | title = Epidemiology: The dominant malignancy | journal = Nature | volume = 513 | issue = 7517 | pages = S2βS3 | date = September 2014 | pmid = 25208070 | doi = 10.1038/513S2a | s2cid = 577152 | doi-access = free }}</ref> The number of smokers in China is rapidly increasing with tobacco killing approximately 3000 people each day.<ref name="Bender_2014" /> The diagnosis of lung cancer is most common within the 50β59-year age bracket.<ref name = "Mattiuzzi_2019" /> Further, it caused 1.8 million deaths in 2020 alone.<ref name = "WHO_Cancer" /> In those aged 14 or younger, [[leukaemia]] is the most frequent form of malignancy with the brain and nervous system subsequent.<ref name = "Mattiuzzi_2019" /> These individuals account for approximately 1% of the cancer mortality rate β about 110,000 children each year.<ref>{{cite journal | author1 = Roser M | author1-link = Max Roser |author2 = Ritchie H | author2-link = Hannah Ritchie |date = 2015 | title = Cancer | journal = Our World in Data | url = https://ourworldindata.org/cancer#citation }}</ref> In the 15β49-year-old age bracket the most common form of malignancy is [[breast cancer]] with [[Liver cancer|liver]] and [[lung cancer]] following.<ref name = "Mattiuzzi_2019" /> Finally, those aged 60 and over mainly develop [[Lung cancer|lung]], [[Colorectal cancer|colorectal]], [[Stomach cancer|stomach]] and [[Liver cancer|liver]] malignancy.<ref name = "Mattiuzzi_2019" /> Uses of "malignant" in [[oncology]] include: *''Malignancy'', ''malignant neoplasm'' and ''malignant tumor'' are synonymous with [[cancer]] *''Malignant [[ascites]]'' *''[[Malignant transformation]]'' Non-oncologic disorders referred to as "malignant" include: *''[[Malignant hypertension]]'' *''[[Malignant hyperthermia]]'' *''[[Otitis externa#Complications|Malignant otitis externa]]'' *''[[Malaria#Signs and complications|Malignant tertian malaria]]'' (malaria caused specifically by ''[[Plasmodium falciparum]]'') *''[[Neuroleptic malignant syndrome]]''
Edit summary
(Briefly describe your changes)
By publishing changes, you agree to the
Terms of Use
, and you irrevocably agree to release your contribution under the
CC BY-SA 4.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)